柳丹博士现任鼎晖投资高级合伙人，负责健康医疗领域的投资，代表项目包括：成都先导(688222.SH)、天境生物(IMAB.O)、和铂医药-B(2142.HK)、九强生物·迈新生物(300406)、集萃药康、新格元生物、齐碳科技等。

在加入鼎晖投资前，柳博士曾在Bain & Company从事大健康领域和大消费领域的管理咨询业务。期间，他服务并负责过多个大型跨国医药和器械企业的战略项目。

柳丹博士在科研、商业、管理、咨询、投资等多领域拥有近二十年健康医疗行业相关经验。

柳丹博士同时担任多个政府、行业协会理事和高级专家，及多个省市级科技和人才项目的审评专家。获评“投资界2021 F40中国青年投资人”、“2021年度最佳医疗大健康领域投资人物TOP 10”、“医疗健康投资卓悦榜40 Under 40.年度医疗健康投资人”、“未来医疗100强.年度青年投资人”。

Dr. Dan LIU is the Senior Partner at CDH Investments, in charge of Healthcare Investments of Venture and Growth Capital. Dr. LIU has led a series of life science investments, including HitGen (688222.SH)、I-Mab (IMAB.O)、Harbour BioMed (2142.HK)、Maxim Biotechnologies (300406), and currently sits on board of nearly 20 portfolio companies.

Prior to joining CDH, Dr. LIU has successively worked at a number of multi-national corporations as management roles and extensive experience in domestic and cross-border healthcare industries. He was the former key professional of Asia Healthcare practice at Bain and Company.

Dr. Liu is a seasoned scientist, consultant and investor with nearly 20 years of experience in Healthcare Sector.